Target intelligence / Profile preview

Intestinal gases, toxins, and poorly soluble compounds

Molecular classification
Other, Non-proteinaceous luminal substances, Metabolic byproducts
01

Overview

Intestinal gases, toxins, and poorly soluble compounds represent a heterogeneous group of non-proteinaceous substances found within the gastrointestinal lumen that serve as focal points for therapeutic intervention. This category includes gases produced by microbial fermentation (such as hydrogen, carbon dioxide, and methane), exogenous toxins from ingestion, and endogenous metabolic products like bile acids or urea (NIH/NIDDK, 2023). Unlike traditional pharmacological targets such as receptors or enzymes, these substances are typically managed through physical or chemical means rather than biochemical signaling pathways. Therapeutic agents like activated charcoal utilize high surface area to adsorb toxins and prevent their entry into the bloodstream, while surfactants like simethicone alter the surface tension of gas bubbles to facilitate their expulsion (PubChem, 2024). In chronic conditions like renal failure, phosphate binders or charcoal-based adsorbents are used to sequester poorly soluble metabolic waste directly within the gut. While effective for symptom relief and emergency toxicology, the primary challenge in targeting these substances is the lack of specificity, which can lead to the unintended sequestration of essential nutrients or other oral medications (FDA, 2022).

Other names
Gastrointestinal luminal toxinsIntestinal gasLuminal noxious substancesPoorly soluble intestinal metabolitesEnteric toxins
02

Mechanism of action

The primary mechanisms include physical adsorption (binding of toxins to a high-surface-area medium), reduction of surface tension (coalescing gas bubbles), and chemical chelation or sequestration to prevent systemic absorption (StatPearls, 2023; Mayo Clinic, 2024).

03

Biological functions

Bacterial fermentation byproductExogenous toxin accumulationEndogenous metabolic waste excretionBile acid metabolism
04

Disease associations

FlatulenceMeteorismAcute poisoningUremiaHyperphosphatemiaDiarrheaIrritable bowel syndrome (IBS)
05

Safety considerations

Non-specific adsorption of co-administered therapeutic drugsConstipationBowel obstructionElectrolyte imbalancesNutrient malabsorption
06

Interacting drugs

Activated charcoal

6 more in the full profile.

07

Biomarkers

Breath hydrogen levelsBreath methane levelsStool toxin assaysSerum urea nitrogenSerum phosphate levels

Beyond the preview

Go deeper on Intestinal gases, toxins, and poorly soluble compounds.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal gases, toxins, and poorly soluble compounds.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call